Pages

Thursday, May 28, 2026

THE ORGAN — I · The Algorithm

The Organ · Post I · The Algorithm
Trium Publishing House
Forensic System Architecture
thegipster.blogspot.com
Est. 2026 · Pennsylvania
The Organ
Post I of VIII
ORG-POST-I  ·  OPTN-CONTRACT-1986-2023  ·  ESTABLISHING ARCHITECTURE

The Algorithm

Thirty-Seven Years · One Contractor · The Most Consequential Private Code in American Medicine

From 1986 to 2023, a single private nonprofit held the federal contract to operate the entire US organ transplant system. It decided who received the kidney, the liver, the heart. Its algorithm determined who lived. In 37 years, the contract was never seriously recompeted. The GAO documented systematic failures. Thirty patients died per day on the waitlist. This is the architecture of who gets to live.

OPTN Contract File · Federal Record · HRSA / HHS ORG-POST-I · DOCKET-REF-01 · ESTABLISHED 1986
Contractor
UNOS · Richmond, VA
Contract Period
1986 – 2023 / 2024
Duration
37–40 years · No rebid
Authority
NOTA 1984 · HRSA Award
Status
Multi-vendor · Post-2023
01 The Position

There are systems whose failures cost money. There are systems whose failures cost time. And there are systems whose failures cost lives — specifically, measurably, with names attached and waiting list positions documented. The United States organ transplant system belongs to the last category. When it fails, the failure has a face, a blood type, and a zip code.

From 1986 to 2023, the operational center of that system was a single private nonprofit organization based in Richmond, Virginia: the United Network for Organ Sharing, known as UNOS. Under a federal contract awarded by the Health Resources and Services Administration, UNOS operated the Organ Procurement and Transplantation Network — the OPTN — the national infrastructure through which donated organs are matched to patients. UNOS maintained the waitlist. UNOS built and ran the matching algorithm. UNOS set allocation policy. UNOS governed the data. For 37 to 40 years, depending on how you count the renewals, one private nonprofit was the architecture of American organ allocation.

The contract was never seriously recompeted. The National Organ Transplant Act of 1984, which created the OPTN, specified a private nonprofit contractor. UNOS, evolving from earlier regional coordination networks, won the initial award and retained it through every subsequent renewal cycle — cycles that critics note were structured as single-vendor processes. The organization that operated the system was also the membership organization for the transplant centers and professionals whose daily practice the system governed. It was, simultaneously, the regulator and the regulated, the standard-setter and the standard-subject, the keeper of the algorithm and the association of the people the algorithm served.

The algorithm determined who lived. The people who built the algorithm were employed by an organization whose members' metrics depended on how the algorithm ran. That is not a conflict of interest. It is the structure of the system.

37
Years · One Contractor
UNOS held the OPTN federal contract from 1986 through 2023 — never seriously recompeted in that span
30+
Deaths Per Day
Patients dying on the transplant waitlist daily at the system's historical rate — approximately 10,000–11,000 per year
100k+
Active Waitlist
Patients on the OPTN waitlist at any given time, predominantly waiting for kidneys
27%
Kidney Discard Rate
Proportion of recovered deceased-donor kidneys discarded rather than transplanted — among the highest of any peer country
02 The Architecture

FSA asks: what is the structure that makes this possible, and who benefits at each layer? The organ system answers that question with a precision unusual even for the most legible institutional architectures. The layers are identifiable. The incentives at each layer are documentable. The insulation is named, funded, and maintained.

The Source is a deceased donor and their family — encountered at the most acute moment of human experience, the hours surrounding a death, and asked to consent to organ procurement by representatives of organizations that are financially incentivized to obtain yes. The family's grief is the entry point of the supply chain. No other supply chain in American life begins in an ICU.

The Conduit is the Organ Procurement Organization — one of 57 regional monopolies, each holding exclusive procurement rights in its designated service area, funded primarily through Medicare reimbursement, with no OPO ever having been fully decertified for poor performance until the reforms of the early 2020s. The OPO recovers the organ. The OPO handles consent. The OPO coordinates with hospitals. And the OPO operates without competition in its territory regardless of its performance.

The Conversion is the algorithm — the UNet matching system, proprietary code owned and operated by a private nonprofit, that takes a recovered organ and produces a ranked list of recipients. The algorithm encodes values: how to weight time on the waitlist against likelihood of survival, how to balance geography against equity, how to handle pediatric patients and sensitized patients and patients with rare blood types. These are not technical questions. They are ethical ones. They were answered, for 37 years, by a private organization whose governing board was populated by the transplant professionals whose centers' outcomes depended on the answers.

The Insulation is the most refined layer in this series. "Science-based allocation." "Evidence-driven policy." "Life-saving mission." "Nonprofit governance." These framings are not false — the allocation is scientifically informed, the mission is genuinely life-saving, the governance is technically nonprofit. But each framing performs the same function: it places the allocation architecture beyond the reach of the challenge that the structure actually warrants. You cannot question an algorithm that is presented as medical science. You cannot challenge a policy that is presented as nonprofit mission. The insulation does not defend the system from criticism. It makes criticism feel inappropriate.

FSA Architecture Map · The Organ ORG-POST-I · REF-ARCH-01
Source
DCD-CONSENT-01
Deceased donor and family — at the moment of death
Consent obtained by OPO representatives in hospital ICUs, often within hours of death. Family grief is the entry point of the supply chain. OPOs are financially incentivized to obtain consent. No other supply chain in American medicine begins here.
Conduit
OPO-REGIONAL-57
57 Organ Procurement Organizations — regional monopolies
Each OPO holds exclusive procurement rights in its designated service area. Medicare-funded. No OPO ever fully decertified for poor performance until 2022+ reforms. Discard rates of 20–29% for kidneys. Wide performance variation with no competitive consequence.
Conversion
UNET-ALGORITHM-V
The algorithm — UNOS's UNet system — proprietary, private
A private nonprofit's code determined who in America received a donated organ. The board that governed the algorithm was populated by transplant professionals whose centers' metrics depended on its outputs. Criticized as outdated and resistant to government data access. The most consequential private software in American medicine.
Insulation
NOTA-MISSION-84
Science-based allocation · Nonprofit mission · Life-saving
The framing that places structural critique out of bounds. Allocation as medical science resists political challenge. Nonprofit governance implies public accountability that the structure does not actually provide. 37 years without serious recompetition, defended by the same language that insulated the system from the scrutiny that might have demanded it.
03 The Founding Law

To understand how a private nonprofit came to hold life-and-death allocation authority for four decades, you need the National Organ Transplant Act of 1984. NOTA was well-intentioned legislation passed at a moment when organ transplantation was rapidly expanding as a medical possibility and the country had no coordinated national system to manage it. The ad hoc regional networks that had developed — most notably the Southeast Organ Procurement Foundation, or SEOPF — were insufficient for national scale.

NOTA's architects made two consequential decisions. First, they created the OPTN as a private nonprofit contractor rather than a government agency — an explicit choice to avoid federal bureaucracy and leverage the expertise of the transplant medicine community. Second, they prohibited compensation for organ donation, establishing the altruistic donation framework that has governed American organ procurement ever since. Both decisions were reasonable responses to the conditions of 1984. Both decisions have consequences that NOTA's authors did not fully anticipate.

The private nonprofit contractor decision created the conditions for UNOS's monopoly. NOTA specified the contractor structure. UNOS, as the organization that had emerged from the existing regional networks, was the natural first contractor. Once in place, the organization accumulated institutional knowledge, relationships, data infrastructure, and political position that made meaningful competition at each renewal cycle increasingly implausible — not by design, but by the ordinary operation of incumbency advantage in a technically complex, relationship-dependent system.

1968
Uniform Anatomical Gift Act
States begin adopting legislation allowing individuals to donate organs at death. No national coordination infrastructure. Regional networks begin developing informally around transplant centers.
1977
SEOPF established · Regional precursor
Southeast Organ Procurement Foundation, predecessor organization to UNOS, establishes early organ matching infrastructure and the SEOPF computer matching system. Builds the institutional relationships and technical architecture that UNOS will inherit.
1984
National Organ Transplant Act · NOTA
Congress creates the OPTN as a private nonprofit contractor rather than a government agency. Prohibits organ sales. Mandates a national network. Creates the structural conditions for a single-contractor monopoly without naming one. UNOS is the natural inheritor of the role.
1986
UNOS awarded first OPTN contract
HRSA awards UNOS the federal contract to operate the OPTN. The 37-year clock begins. UNOS operates the waitlist, matching algorithm (UNet), data infrastructure, and sets allocation policy. No other organization bids successfully across the subsequent renewal cycles.
1986–2020
Contract renewals · Single-vendor structure
Multiple contract renewals across administrations. GAO and OIG reports document performance gaps. Senate Finance Committee investigations detail failures in oversight, IT systems, complaint handling, and conflicts of interest. UNOS retains the contract. No OPO is fully decertified. Reform pressure builds.
2020
CMS OPO performance metrics reform
First objective performance metrics for OPOs — donation and transplant rates — are established, enabling comparison and potential decertification. A significant structural reform that creates the possibility of accountability for the first time in the conduit layer.
2023
Securing the US OPTN Act · Multi-vendor rebid
Congress passes legislation formally ending the single-contractor model. HRSA announces OPTN Modernization Initiative. Contract broken into multiple competitive awards — IT, operations, safety, governance. UNOS retains some components; others awarded to new vendors. The 37-year monopoly formally ends. The post-monopoly architecture is still being assessed.
04 The Accountability Structure

The oversight structure of the organ transplant system was, for most of its history, a maze of fragmented jurisdictions with no single actor clearly responsible for the system's performance. HRSA oversaw the OPTN contract. CMS oversaw OPO certification and reimbursement. The OPTN board — whose membership UNOS substantially controlled — set allocation policy. No agency had both the authority and the mandate to hold the entire system to account for the thing that mattered most: how many patients died waiting while recoverable organs were discarded.

Oversight Architecture · US Organ Transplant System · Pre-2023 ORG-POST-I · ACC-01
Entity
Nominal Authority
Actual Accountability Gap
HRSA / HHS
Awarded and oversaw the OPTN contract. Received UNOS performance reports. Authority to rebid the contract.
Critical Gap — Did not seriously rebid for 37 years. No independent performance evaluation mechanism. Dependent on UNOS's own data for oversight.
CMS
Certified OPOs. Reimbursed organ recovery costs via Medicare. Authority to decertify underperforming OPOs.
Critical Gap — No OPO was fully decertified for poor performance until 2022+. Metrics were outcome-agnostic until 2020 CMS rule change. Regional monopolies operated without competitive consequence.
OPTN Board
Set allocation policy. Governed the matching algorithm. Approved standards for transplant centers and OPOs.
Structural Conflict — Board populated by transplant professionals whose centers' metrics were governed by board decisions. UNOS as membership organization meant the regulated set the regulations.
Congress
Senate Finance Committee oversight hearings. GAO investigation authority. Appropriations leverage.
Delayed — Senate Finance Committee (Wyden/Grassley) investigations documented failures from 2019–2022. Meaningful legislative response came in 2023 — 37 years after the monopoly was established.
UNOS
Operated the system. Maintained the waitlist. Ran the matching algorithm. Set allocation policy via OPTN board.
Self-Regulating — The operator was also the standard-setter. Member fees from transplant centers funded the organization. The regulated funded the regulator. The 2023 rebid ended this formally; its actual resolution is ongoing.
Transplant Centers
Listed patients. Accepted or declined organ offers. Reported outcomes to OPTN.
Misaligned — Center incentives under "volume = quality" metrics created risk aversion toward marginal organs, contributing to high discard rates. Centers paid member fees to UNOS, creating financial relationship between regulated and regulator.
05 What the GAO Found

The Government Accountability Office examined the organ transplant system across multiple reports spanning decades. Senate investigators documented dozens of serious errors — transportation failures, organs arriving with tire tracks on coolers, wrong blood type transmissions, infections passed to recipients, communication breakdowns that resulted in organs expiring before they could be used. One analysis linked approximately 70 deaths to OPTN and OPO operational failures in the decade from 2010 to 2020.

The operational failures were serious. But the structural finding was more damaging: the oversight architecture that should have detected and corrected these failures had not done so, because the architecture was not designed to. HRSA oversaw a contractor that provided HRSA with its own performance data. CMS certified OPOs that were never decertified. The OPTN board governed a system whose members funded the board's operating organization. The checks were present on paper. They were not functional in practice.

A 2026 GAO report — after the formal transition to multi-vendor contracting had begun — urged HHS and HRSA to strengthen modernization plans and risk management frameworks. UNOS agreed with the recommendations. The willingness to agree with recommendations for improvement after a 37-year monopoly has ended is not the same as accountability for what the monopoly produced.

FSA Note · Insulation Layer

The organ system's insulation layer is structurally different from the plasma industry's. Plasma insulation is linguistic — the word "donation" doing the work. Organ insulation is jurisdictional — the diffusion of accountability across HRSA, CMS, the OPTN board, and Congress such that no single actor was clearly responsible for the system's aggregate performance. When everything is everyone's responsibility, nothing is anyone's accountability. The system produced 30 deaths per day on the waitlist. The question of whose failure that was has never been cleanly answered, because the architecture was designed — not by conspiracy, but by the structural logic of distributed oversight — to make it unanswerable.

06 This Series

The organ transplant system is the most consequential allocation architecture in American medicine. It decides, through a combination of algorithm, policy, and institutional structure, who among the 100,000+ patients on the waitlist receives the next available organ. The decisions it makes are irreversible in both directions — a wrong allocation cannot be recalled, and a patient who dies waiting cannot be restored.

This series applies FSA to that architecture in full — the consent obtained in grief, the 57 regional monopolies that recover the organs, the algorithm that allocates them, the board that governed the algorithm, the contract that was never recompeted, and the country that built a better model and chose not to use it. Eight posts. The system examined layer by layer, the insulation removed, the structure named.


The Organ · Series Architecture · Eight Posts ORG-SERIES · MAP-01
I
The Algorithm
Establishing architecture · 37-year monopoly · the most consequential private code in American medicine
II
The List
The waitlist as managed queue · 100k+ patients · 30 deaths per day · geographic and racial disparity embedded in allocation
III
The Regional Monopoly
57 OPO territories · no competition, no decertification, no consequence · the procurement gap mapped
IV
The Discard
20–29% kidney discard rate · risk aversion as rational center behavior · the algorithm's role in waste
V
The Board
Who governed UNOS · transplant professionals self-regulating · member fees funding the regulator
VI
The Contract
NOTA 1984 · how a private nonprofit became a 37-year monopoly · the rebid that wasn't
VII
The Spain Divergence
52+ donors per million · the Spanish Model as structural contrast · what different incentives produce
VIII
The Modernization
2023 Securing the US OPTN Act · multi-vendor rebid · whether competition replaced capture or redistributed it

The Blood Economy — Post VIII — The Renewable Crop

The Blood Economy · Post VIII · The Renewable Crop
Trium Publishing House
Forensic System Architecture
thegipster.blogspot.com
Est. 2026 · Pennsylvania
The Blood Economy
Post VIII of VIII · Series Complete
Final Post · Series Synthesis

The Renewable
Crop

Synthesis · What Sustains It · What Threatens It · What It Reveals

The human body regenerates plasma in forty-eight hours. The industry built around that fact is not fragile — it is load-bearing, globally integrated, and insulated at every layer. But it rests on conditions that are beginning to shift: biologically, legally, technologically, demographically. This post names what the system is, what threatens it, and what it discloses about the country that built it.

Post I–II
Source + Language
Human body as subscription asset. "Donation" as load-bearing insulation for a paid transaction.
Post III–IV
Conduit + Arbitrage
Sited by poverty density. Extended to international wage differential at the border. One in ten liters on an injunction.
Post V–VI
Institutional + International
Regulatory capture via PPTA. Congressional Plasma Caucus at 40+. European alibi removes external reform pressure.
Post VII
Feedback Loop
Poverty drives supply. Public insurance funds demand. Extraction and distribution occupy the same census tract.
01 The Name

A crop is something grown, harvested, and grown again. The word implies a relationship between a resource and its cultivation — not extraction in the sense of a mine, which is depleted, but extraction in the sense of agriculture, which is sustained by the biology of regrowth. The plasma industry is, in this precise sense, a crop economy. The resource regenerates. The harvest recurs. The farm is a human body, and the farming season runs fifty-two weeks a year.

The word is uncomfortable. It is meant to be. The discomfort is the distance between what the industry calls the transaction — donation, compensation for time, voluntary participation — and what the transaction structurally resembles when you remove the insulation and look at the underlying geometry. A person arrives twice a week. A biological product is extracted. A payment is made. The person leaves. They return on Thursday.

None of this language accuses anyone of malice. The crop metaphor is not a moral verdict — it is a structural description. The body is treated, by the architecture of this industry, as a renewable biological substrate. That is what the industry is built on. That is what this series has mapped.

The most important fact about a renewable resource is not that it renews. It is that the renewal is taken for granted. The crop is expected to grow back because it always has. The question the farmer never asks is what happens to the soil.

02 What Sustains the System

Before examining what threatens the system, it is worth being precise about what sustains it — because the sustaining forces are stronger than the threatening ones, and any honest assessment of the blood economy's future must begin with that asymmetry.

Demand Factor
IgG Has No Substitute
Immunoglobulin G cannot be replicated at therapeutic scale by recombinant technology. Demand is growing 6–8% annually driven by better diagnosis of autoimmune and neurological conditions, aging populations, and expanded indications. The industry's core product faces no technological disruption horizon. Plasma-derived IgG will remain essential for the foreseeable treatment future.
Supply Factor
Economic Precarity Is Reliable
The donor pool is sustained by the same economic conditions that produced it. Federal minimum wage unchanged since 2009. Housing costs rising. Post-pandemic financial fragility. The expanding middle-income donor cohort (Post III) reflects economic stress broadening upward. The industry does not need to recruit donors. It needs to remain accessible to populations that economic conditions continuously produce.
Regulatory Factor
Capture Is Entrenched
PPTA-FDA relationship is institutionalized across decades. Congressional Plasma Caucus at 40+ members, growing. Industry-funded evidence base for safety limits is the regulatory record. Any move toward stricter caps or unpaid-only requirements faces a fully organized, well-resourced, politically connected opposition with legitimate patient access arguments to deploy.
International Factor
The World Needs the Supply
No country or bloc has demonstrated the capacity to replace US paid plasma supply at scale through voluntary donation. European self-sufficiency goals remain unmet after decades. Global demand growth outpaces voluntary supply growth everywhere it has been tried. The dependency is structural, not transitional. The US "plasma OPEC" position is load-bearing for global patient populations with no alternative.
03 What Threatens It

The sustaining forces are real and durable. The threatening forces are real but slower, more uncertain, and partially dependent on policy and legal outcomes that remain unresolved. The system is not stable in perpetuity. It is stable for now — which is a different condition.

System Threat Assessment · The Blood Economy · 2025–2026 TBE-POST-VIII · THREAT-01
Threat
Mechanism
Supply Impact
Timing
Border visa final ruling
Federal court resolves underlying "labor for hire" question against industry. Injunction lifted. Cross-border donor access ends or is severely restricted. ~10% of US plasma supply disrupted.
High (10%)
Near-term · Unresolved
Gene therapy erosion
Roctavian (hemophilia A) and Hemgenix (hemophilia B) provide long-term factor expression after one-time treatment. Continued uptake reduces demand for plasma-derived and recombinant clotting factors. Does not affect IgG demand.
Low–Med (niche)
Long-term · Gradual
Donor safety scrutiny
2026 Canadian deaths at Grifols centers. NYT investigation. Independent long-term cohort data absent. If adverse findings emerge, regulatory pressure to reduce maximum frequency could materially reduce supply per donor.
Medium
Near-term · Building
Tariff and trade disruption
Import tariffs on biologics inputs, trade policy shifts, or export restrictions could disrupt the cold-chain logistics of a globally integrated fractionation system. Particularly relevant for cross-border supply and European distribution.
Medium
Near-term · Active
Corporate concentration failure
Grifols financial stress (documented 2024–2025). High debt load, investor scrutiny. If a major fractionator encounters insolvency or capacity reduction, the concentrated supply chain has limited redundancy. Single-point failure risk is inherent to four-company control.
High (if realized)
Mid-term · Monitored
Recombinant IgG development
Long-term research into engineered immunoglobulins. Not commercially available at scale. Would fundamentally alter the industry if achieved. Timeline uncertain. No viable near-term substitute for plasma-derived IgG exists.
High (if realized)
Long-term · Speculative
Wage growth / economic recovery
If wage growth, housing cost stabilization, or expanded social programs reduce the economic precarity driving donor supply, the donor pool contracts. The system's supply depends on conditions it has no direct control over — and no interest in resolving.
Medium
Long-term · Structural
04 The Series Findings

Eight posts. One system. The following table is the complete FSA record of this series — each post's subject, its analytical layer, and its central finding stated in a single sentence.

The Blood Economy · Series Record · FSA Findings TBE-SERIES · RECORD-COMPLETE
I
The OPEC of the Body
The United States produces 70% of the world's plasma-derived medicines because it pays donors — and the industry built to collect, process, and distribute that plasma constitutes the largest bio-extraction economy in human history.
II
The Word Donation
The FDA's decision to apply "paid/volunteer" labeling only to transfusion blood — not source plasma — created a regulatory space in which paid collection could be normalized under a voluntary framework, and a single word bears the full weight of that insulation.
III
The Siting Decision
Collection centers are built in high-poverty census tracts by design, not coincidence — the geography of economic need and the geography of plasma supply are the same map, optimized for cost per liter.
IV
The Border Liter
One in ten liters of American plasma crosses an international border before it enters the supply chain, extracted from Mexican nationals using tourist visas in a legal gray zone maintained by federal injunction since 2022.
V
The Caucus and the Standard
The industry that funds the safety studies, grew the Congressional Plasma Caucus to 40+ members, and participates in the FDA guidance process is also the primary beneficiary of the standards those processes produce — regulatory capture operating through the ordinary accumulation of proximity and expertise.
VI
The European Alibi
European prohibition of paid plasma donation is not a critique of the American system — it is part of the American system's insulation, allowing Europe to maintain ethical rectitude domestically while importing the product of the practice it formally condemns, at a scale that makes US reform politically unthinkable.
VII
The Feedback Loop
The blood economy extracts from economic precarity, processes through concentrated corporate infrastructure, and distributes back into the same socioeconomic stratum via public insurance — public money enters at both ends, and the poverty that drives supply is the same condition that limits treatment access.
VIII
The Renewable Crop
The system is not fragile — it is load-bearing, insulated at every layer, and sustained by conditions (IgG demand growth, economic precarity, regulatory capture, European dependency) that show no near-term signs of resolution; what it discloses about American bio-political economy is the degree to which the most essential supply chains rest on the most precarious foundations.
05 What It Reveals

The blood economy is not an aberration. It is an expression — a particularly legible example of a pattern that recurs across American economic life. The pattern: identify a biological or physical resource held by individuals without economic alternatives. Build infrastructure to extract it. Insulate the extraction with language that frames it as mutual benefit. Process the resource through concentrated corporate infrastructure. Distribute the finished product at prices that require institutional mediation. Capture the regulatory process that might otherwise constrain the extraction. Maintain the conditions that sustain the supply.

This pattern appears in how the United States manages gig labor, prison labor, military recruitment, organ donation waitlists, and clinical trial participation. The plasma industry is not unique in its structure. It is unusually transparent about that structure, because the biological mechanics of the extraction make the supply chain literally visible — you can see the needle go in, the bag fill up, the compensation change hands. Most extraction economies are less legible. This one is harder to look away from.

The blood economy also reveals something specific about the relationship between market logic and biological necessity. The industry exists because patients genuinely need the medicines it produces. That need is not manufactured. The suffering it addresses is not performative. The industry has a legitimate claim to the patient access argument — because the argument is true. Remove the supply, and people die. This is the system's most durable insulation, because it is not insulation at all. It is a fact.

FSA Note · System Disclosure

The blood economy discloses the following about American bio-political economy: that the country is capable of building highly efficient extraction systems from human biological material; that it is capable of insulating those systems against reform through language, regulation, and institutional capture; that it is capable of making those systems genuinely necessary to global patient populations before anyone has seriously evaluated whether they should exist in their current form; and that the populations who bear the physical costs of those systems are structurally excluded from the institutional processes that set the terms of their participation. None of this is a secret. All of it is, in ordinary public discourse, unnamed.

06 The FSA Method, Applied

Forensic System Architecture begins with a question: what is the structure that makes this possible, and who benefits at each layer? The blood economy answers that question in full. The structure is the four layers mapped in Post I — source, conduit, conversion, insulation — each examined in detail across this series. The beneficiaries at each layer are identifiable: donors receive modest compensation, companies capture the margin, regulators maintain the framework, importing nations maintain their alibi, and patients receive medicines they cannot afford to produce for themselves.

The FSA method does not require a villain. It requires only that the structure be named — that the insulation be removed, the layers be made visible, and the flows of benefit and cost be traced to their actual destinations. What the method finds, in this case, is a system that is simultaneously life-saving and extractive, simultaneously necessary and inequitable, simultaneously transparent in its mechanics and opaque in its moral self-presentation.

The blood economy will not be reformed by this analysis. It will not be reformed by any single analysis. Systems of this scale and this depth of institutional integration do not yield to exposure. What they yield to, eventually, is the accumulation of documented record — the kind of record that makes it impossible to claim, in the future, that no one knew what the structure was.

This series is that record. Eight posts. One system. Beneath the words, the truth.

Series Closing Statement · The Blood Economy · Trium Publishing House

The American plasma industry supplies seventy percent of the world's plasma-derived medicines. It is built on the bodies of low-income Americans and Mexican nationals. It is insulated by a single word — donation — and by a regulatory apparatus, a congressional caucus, and a European moral posture that together make that word difficult to challenge without threatening the supply that patients depend on.

The feedback loop closes in the same neighborhood where it opens. The donor and the patient are not the same person. They are the same community — at different points in a system that needs them both and protects neither.

This is not a scandal. It is a structure. The difference matters. Scandals can be resolved. Structures must be named, documented, and held in view — until the conditions that make them possible change, or until enough people understand what they are that the conditions become harder to maintain.

We have tried to name it precisely.

Sub Verbis · Vera  ·  Beneath the words, the truth.
Randy Gipe · Claude / Anthropic · Trium Publishing House Limited · 2026

The Blood Economy — Post VII — The Feedback Loop

The Blood Economy · Post VII · The Feedback Loop
Trium Publishing House
Forensic System Architecture
thegipster.blogspot.com
Est. 2026 · Pennsylvania
The Blood Economy
Post VII of VIII
Post VII  ·  The Circuit Closed

The Feedback
Loop

The Donor and the Patient · One Population · Two Transactions

The person who sells plasma on Tuesday is not the person who receives immunoglobulin on Friday. But they are likely the same kind of person — same income stratum, same neighborhood, same insurance status. The blood economy extracts from poverty and distributes back into it, mediated by corporate infrastructure and public insurance. The loop is not metaphor. It is the system's completed geometry.

🩸
Low-income
Donor
Collection
Center
Fractionation
Corporate
💊
IVIG / Albumin
Medicine
🏥
Medicaid /
Insurance
🩺
Low-income
Patient
↺   Same population · different transaction · the loop closes
01 The Geometry of the System

Post I described the blood economy as a four-layer architecture. Six posts have examined each layer in detail — the source, the conduit, the conversion, and the multiple forms of insulation maintaining the whole. This post steps back from the layers and looks at the shape the complete system makes when you draw it as a circuit.

The circuit begins with a body. It ends with a body. Between those two bodies — both of them belonging to people in the lower half of the American income distribution — lies the entire apparatus of corporate infrastructure, regulatory framework, linguistic insulation, international supply chain, and public insurance that this series has mapped. The system extracts biological material from economic need. It processes that material into life-saving medicine. It delivers that medicine, predominantly via public insurance, back to populations that overlap substantially with the populations from which the raw material was extracted.

This is not a revelation about individual bad actors. The donors choose to donate, within the constraints of their economic reality. The patients need the medicines that keep them alive. The companies operate legally. The regulators follow their mandates. The loop is not the product of malice. It is the product of structure — a system that was built, incrementally and without coordinating intent, to accomplish exactly this outcome.

The most important thing about the feedback loop is that it closes. The poverty that drives supply and the poverty that limits treatment access are not two separate problems that happen to involve the same kind of people. They are the same condition, encountered twice by the same system — once as resource, once as market.

02 The Demographic Overlap

The overlap between the donor population and the patient population is not identical — it is not a one-to-one correspondence. It is a population-level overlap that becomes visible when you place the demographic profile of plasma donors alongside the demographic profile of Americans who receive plasma-derived medicines through public insurance programs.

The donor population, as documented across posts III through V, is predominantly low-income, disproportionately younger, concentrated in high-poverty urban census tracts, and economically motivated. The patient population for plasma-derived medicines — immunoglobulins, in particular — is medically defined by diagnosis rather than income. But access to diagnosis and access to treatment are both mediated by insurance coverage, which is itself a function of income and employment. The patients who receive IVIG through Medicaid are, by definition, low-income. The geographic and socioeconomic distribution of Medicaid-covered immunoglobulin therapy and the geographic distribution of plasma collection centers are not identical maps. But they describe overlapping communities.

Population Overlap · Plasma Donors vs. PDMP Patients · Demographic Profile TBE-POST-VII · DEMO-01
Donors
Low-income
High-poverty tract
Under 35
Economically motivated
Patients
Medicaid / uninsured
Chronic condition
All ages
Access-constrained
LOW-INCOME
URBAN
MEDICAID-ELIGIBLE
Donor Profile Only
Economically motivated to donate. Repeat participation budgeted as income. Young, healthy enough to meet FDA donor eligibility criteria. Geographic proximity to collection centers.
Shared Demographic Zone
Low-income. High-poverty urban neighborhoods. Medicaid-eligible. Limited financial buffers. Public insurance as primary healthcare access point. Subject to structural economic precarity.
Patient Profile Only
Medically diagnosed condition requiring plasma-derived therapy. Dependent on insurance coverage for treatment access. Treatment cost ($1,000s per course) only accessible via Medicaid, Medicare, or private insurance.
03 The Public Money Flows Twice

The blood economy has a fiscal dimension that is rarely examined as a unified system. Public money — taxpayer-funded — enters the circuit at two separate points, and the fact that it enters twice is obscured by the architecture's insulation layers.

The first entry point is the economic conditions that produce the donor pool. The inadequacy of wages, the insufficiency of social safety nets, the housing cost pressures that make $50 per plasma session a meaningful income supplement — these are conditions that public policy has failed to resolve, and that failure is what makes the donor supply reliable. The government does not pay donors directly. But the government's failure to provide adequate economic support is what drives donors through the collection center door. Public inaction creates the supply.

The second entry point is explicit: Medicaid and Medicare pay for plasma-derived medicines on behalf of low-income and elderly patients. When a Medicaid beneficiary receives an immunoglobulin infusion, the federal and state governments pay the pharmaceutical company — which may be one of the same companies that collected the donor's plasma — for the finished product. Public money flows to the fractionator at the end of the same chain that public inaction helped fill at the beginning.

Public Money · Two Entry Points · The Fiscal Loop TBE-POST-VII · FISCAL-01
Public Inaction
Insufficient wages · inadequate safety nets
Government failure to ensure adequate wages and economic security creates the donor pool. The federal minimum wage of $7.25/hr has not been raised since 2009. Housing costs have risen substantially. Plasma income fills the gap public policy does not.
→ Creates donor supply
Donor
$30–70
Donor
Plasma · 2× per week
Collection, fractionation, 7–12 month batch processing. Vertical integration by four companies. $35–40B global market. Donor compensation approximately $4.7B in 2025 against total fractionation market revenue.
→ Corporate value capture
Fractionator
$35–40B
Medicaid · Medicare
Public insurance reimbursement
Federal and state government pays for plasma-derived medicines on behalf of low-income and elderly patients. IVIG infusion costs thousands of dollars per treatment course — inaccessible without insurance. Medicaid covers a significant share of US immunoglobulin therapy costs.
→ Public funds reach fractionator twice
Fractionator
Second revenue stream from same supply chain
04 The Vignette

Architecture can be mapped in tables and diagrams. But the feedback loop is also a human experience, and it deserves to be held in that register before it is reduced entirely to structure. The following vignette is composite and illustrative — it is not the account of a specific individual. It is drawn from documented research on donor experiences, patient access patterns, and the socioeconomic distribution of plasma donation and plasma-derived medicine use.

Composite Illustration · Drawn from documented research · Not a specific individual

She goes on Tuesday and Thursday. The center is three blocks from the bus stop, between a check-cashing place and a dollar store. She has been going for eight months. The session takes about seventy minutes now — they have new machines. She brings a book.

The money goes to rent. Not all of it — the rent is more than twice what she makes in a week of donations. But it covers part. Her employer cut her hours. She applied for Medicaid. The application is pending.

Two miles away, in the same city, a child receives an immunoglobulin infusion at a hospital clinic. The child has primary immunodeficiency — her immune system does not produce antibodies. Without the infusions, every ordinary infection becomes a serious threat. The family pays nothing at the window. Medicaid covers it.

The plasma in that infusion bag was pooled from thousands of donations. Some of those donations were made at a center three blocks from a bus stop. The woman who made them does not know this. The child who received them does not know this. The system that connects them does not require either of them to know.

The loop requires no coordination, no awareness, and no malice. It requires only structure — and the structure is in place.
05 The Loop Anatomy

Laid out in sequence, the feedback loop has seven steps. Each has been examined in detail across this series. Here they are together — the complete circuit, from body to body.

The Feedback Loop · Complete Circuit · Seven Steps TBE-POST-VII · LOOP-01
1
Economic Precarity Creates the Donor Pool
Insufficient wages, rising housing costs, inadequate safety nets, and concentrated urban poverty produce a population for whom $50 per plasma session is a meaningful income supplement. The supply is not voluntary in any unconstrained sense. It is economically driven.
2
Collection Infrastructure Is Sited by Poverty Density
~80% of centers in high-poverty census tracts. Deliberately placed near public transit in poverty-dense neighborhoods. The geography of need is the geography of supply. The infrastructure finds the precarity.
3
Plasma Extracted at FDA-Maximum Frequency
Up to 104 times per year, twice weekly. The body is not a one-time asset. It is a subscription. The renewable biology of plasma regeneration is the economic foundation of the industry.
4
Corporate Conversion at Concentrated Scale
Four companies control the chokepoint. Fractionation takes 7–12 months. Global market: $35–40B. Donor compensation (~$4.7B annually) is a small fraction of end-product revenue. The margin between raw material cost and finished product price is the architecture of the industry.
5
Medicines Priced for Insured Markets
IVIG: thousands per treatment course. Albumin, clotting factors: significant ongoing costs. Uninsured patients cannot access the product their neighbors' bodies helped produce. The price wall is maintained by the same concentration that controls the supply chain.
6
Public Insurance Bridges the Access Gap
Medicaid and Medicare cover plasma-derived medicines for low-income and elderly patients. The same tax base that failed to produce adequate wages funds the treatment those inadequate wages helped supply. Public money enters the circuit twice.
7
Patient Population Overlaps Donor Population
Medicaid-covered IVIG patients are low-income by definition. Plasma collection centers are sited in low-income neighborhoods by design. The extraction point and the distribution point are the same community.
The loop closes here. The economic precarity that drives Step 1 is not resolved by the system — it is required by it. A donor population that achieved financial security would reduce supply. The system is not designed to exit the loop. It is designed to sustain it.
06 What the Loop Means

The feedback loop does not make the blood economy evil. The medicines are real and necessary. The donors' participation is, within their economic constraints, genuinely chosen. The patients who receive IVIG are genuinely helped. None of this is false.

What the loop reveals is that the system's benefits and costs are not distributed across the same populations. The financial benefits — the margin between donor compensation and end-product revenue — accrue to the four companies that control the processing chokepoint. The medical benefits accrue to patients, across income levels, weighted toward those with insurance access. The physical costs — the bodily demands of twice-weekly apheresis, the health risks of high-frequency donation, the cumulative toll on donors whose nutrition and health baseline may already be compromised by poverty — accrue almost exclusively to the people at the source layer.

A system in which the people who bear the costs are not the people who capture the benefits is not an anomaly. It is a design. The blood economy did not set out to create that design. It arrived at it through the accumulation of individually rational decisions — regulatory, commercial, behavioral — that each made sense in isolation and that together produced a circuit from poverty to poverty, mediated by the largest bio-extraction industry in the world.

$4.7B
Donor Compensation
Total paid to US plasma donors in 2025 — against a $35–40B global fractionation market
$0
Uninsured Access
What an uninsured patient can afford toward a several-thousand-dollar IVIG infusion course without financial assistance
Public Money Entry
Public funds shape the system at both ends: policy failure creates donor supply; Medicaid pays for treatment delivery
FSA Note · The Closed Circuit

The feedback loop is the structural finding that ties this series together. Post I described four layers of architecture. Posts II through VI examined each layer and its insulation. Post VII shows what those layers produce in aggregate — a closed circuit in which economic precarity is converted into biological supply, processed through concentrated corporate infrastructure, and returned to the same economic stratum as priced medicine, subsidized by public insurance funded by the same tax base that failed to prevent the precarity in the first place. The architecture is not hidden. It is simply not, in ordinary public discourse, named as what it is.


Final Post · Post VIII · The Renewable Crop — Synthesis, sustainability, what threatens the system, what it reveals about American bio-political economy. The series closes.